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Abstract
Background: Patients on peritoneal and hemodialysis have accelerated atherosclerosis associated
with an increase in cardiovascular morbidity and mortality. The atherosclerosis is associated with
increased arterial stiffness, endothelial dysfunction and elevated oxidative stress and inflammation.
The aims of this study are to investigate the effects of peritoneal and hemodialysis on arterial
stiffness, vascular function, myocardial structure and function, oxidative stress and inflammation in
incident patients with end stage kidney disease.
Methods: This is an observational study. Eighty stage five CKD patients will be enrolled and
followed for one-year. Primary outcome measures will be changes in 1) arterial stiffness measured
by aortic pulse wave velocity, 2) oxidative stress assessed by plasma F2 isoprostanes and 3)
inflammation measured by plasma pentraxin-3. Secondary outcomes will include additional
measures of oxidative stress and inflammation, changes in vascular function assessed using the
brachial artery reactivity technique, carotid artery intimal medial thickness, augmentation index and
trans thoracic echocardiography to assess left ventricular geometry, and systolic and diastolic
function. Patients will undergo these measures at baseline (6–8 weeks prior to starting dialysis
therapy), then at six and 12 months after starting dialysis.
Discussion: The results of this study may guide the choice of dialysis modality in the first year of
treatment. It may also lead to a larger study prospectively assessing the effect of dialysis modality
on cardiovascular morbidity and mortality.
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End stage kidney disease (ESKD) patients undergoing
dialysis have a substantially increased risk of cardiovascu-
lar morbidity and mortality[1] In 2007, 2311 new
patients started dialysis in Australia and New Zealand but,
unfortunately, many of these patients will die of cardio-
vascular disease. (ANZDATA 2007) The decision to
undergo either peritoneal or haemodialysis is based on a
number of factors. One of the important issues is the
potential damage the renal replacement therapy may have
on the cardiovascular system. Currently, little is known
regarding the differential effects of the dialysis modalities
on the cardiovascular system.
Oxidative stress and inflammation are associated with the
development of cardiovascular disease in dialysis patients
[1,2]. The mechanisms are believed to involve arterial
stiffening leading to impaired vascular function [3]. In
addition, vascular and myocardial dysfunction are also
prominent, increasing the likelihood of cardiovascular
disease morbidity and mortality in dialysis patients [4]. A
number of studies have documented that peritoneal dial-
ysis is associated with decreased levels of oxidative stress
and inflammatory markers compared to haemodialysis
[5]. A small number of trials have extended this work to
determine associations between oxidative stress and
inflammation with vascular or myocardial structure and
function with equivocal results [4,6]. To our knowledge,
only a few cross sectional studies have compared the
effects of different dialysis therapies on surrogate markers
of cardiovascular disease [7,8]. As yet, no study has com-
pared the changes in these markers over time in incident
dialysis patients.
Measures of arterial stiffness such as aortic pulse wave
velocity (PWV) predict morbidity and mortality in
patients with kidney disease [9]. Numerous studies have
reported that the elevated levels of oxidative stress and
inflammation in this population [10-14] are associated
with arterial stiffness [15]. Therefore, the purpose of this
study is to assess the effect of peritoneal and hemodialysis
on arterial stiffness, vascular function, oxidative stress and
inflammation and myocardial structure and function.
Comparing the effects of dialysis modalities on surrogate
cardiovascular markers over time will provide unique
important information to assist in the treatment of
patients with ESKD. A randomised controlled trial assess-
ing this would be ideal but unethical in Australia as
patients are generally given a choice between hemodialy-
sis and peritoneal dialysis.
Methods
General Considerations and Study Population
This is a multi-centre, one-year prospective observational
study utilising convenience sampling. Eighty stage five
CKD patients, not yet on dialysis, will be enrolled. They
will commence either haemodialysis or peritoneal dialysis
according to clinical need and personal preference after
undertaking pre-dialysis education. They will be followed
for one year after the commencement of their treatment
modality. Although this design may be a limitation it is
the only ethical one for our aims.
Location
Patients will be recruited from the Royal Brisbane and
Women's Hospital, Brisbane, and the Launceston General
Hospital and Satellite Renal Unit Burnie which service
populations of approximately 1.2 million and 250,000
respectively.
Inclusion Criteria
Patients must satisfy the following criteria prior to enter-
ing the study: 1) age > 18 and < 85 years, 2) an estimated
glomerular filtration rate (eGFR) of < 15 mL/min/1.73
m2, 3) undertaken pre-dialysis education program, 4) pro-
vide written informed consent.
Exclusion Criteria
Failure to gain consent or inability to tolerate glyceryl trin-
itrate (GTN).
Allocation
The trial is utilising a sample of convenience recruiting
participants whom will likely commence either haemodi-
alysis or peritoneal dialysis within three-six months.
Approximately six-eight weeks prior to commencing their
treatment modality, all eligible patients will undergo
baseline measurements of vascular and myocardial struc-
ture and function and blood will be collected for the oxi-
dative stress and inflammatory measures. They will then
undergo the same measurements at six and 12 months
after commencing their chosen treatment.
Selection and Recruitment of Patients
The nephrologists, trial co-ordinators and research assist-
ants will be responsible for the selection of all eligible
patients to be approached. Medical records will be
screened prior to attendance at pre-dialysis education clin-
ics. At this stage patient preference for dialysis treatment
modality is discussed. After explanation of the study, the
subject will be provided with a patient information sheet
and informed consent form. The subject will then be
asked to take this away with them and arrangements will
be made to follow up via a telephone call. If the subject
agrees to participate, they will sign the consent form.
Blood Sampling
A trained phlebotomist will take 40 millilitres of blood
during visits to their hospital pathology laboratory or
taken on dialysis once this has started.Page 2 of 7
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The Tasmanian Statewide Scientific and Ethics Committee
has approved the study. The Ethics Committee will be
provided with annual reports of the trial progress and will
promptly receive all adverse event reports.
Primary Objectives and Primary Outcome Measures
The primary objectives are to assess the effects of dialysis
modality on arterial stiffness and oxidative stress and
inflammation. The hypothesis is that peritoneal dialysis
will significantly improve the rates of change in these
measures compared with hemodialysis. The primary out-
come measures are outlined below.
Arterial stiffness
The primary outcome for arterial stiffness will be aortic
PWV. Carotid to femoral PWV will be derived by electro-
cardiography-gated sequential applanation tonometry
(SPT-301 Mikro-Tip, Millar Instruments, Houston, Texas)
using the foot-to-foot method (SphymoCor™ 7.01 AtCor,
Sydney, Australia) [16]. Testing is performed in a temper-
ature-controlled room and after 5–10 minutes rest with
the subject in the supine position prior to the first meas-
ure. Two measures will be averaged for the estimation of
aortic PWV.
Oxidative stress and inflammation
The primary outcome measure for oxidative stress will
plasma F2 isoprostane measured using gas chromatogra-
phy mass spectrometry [17] and for inflammation, pen-
traxin 3 using an ELISA assay [18].
Secondary Objectives and Secondary Outcome Measures
Secondary objectives are to assess the effects of dialysis
modality on vascular structure and function, myocardial
structure and function and additional measures of arterial
stiffness, oxidative stress and inflammation.
Vascular Structure and Function
Carotid Intimal Media Thickness (CIMT) will be used to
measure structural alterations of the posterior wall of both
the left and right common carotid arteries. CIMT refers to
the combined thickness of the intimal and medial layers
of the carotid arterial wall [19]. This corresponds to the
inner and outer echogenic lines seen on the B-mode ultra-
sound image [20]. The CMIT will be assessed using a 12
MHz linear array transducer and ultrasound scanner
(Vivid i, GE Healthcare, USA). Images will be acquired
from the anterior, posterior and lateral planes of the right
and left common carotid arteries. The thickness will be
measured one to two centimetres proximal to the bifurca-
tion and during cardiac diastole from the far wall only as
there are technical and acoustic difficulties encountered
when measuring the near wall thickness [20]. For the pur-
pose of this study, the average of these six recordings will
be used. CIMT assessment will be performed in the
plaque-free arterial wall (an atherosclerotic plaque being
defined as an echo-structure protruding into the vascular
lumen and a thickness greater by at least 50% than neigh-
bouring sites [21].
Brachial artery reactivity (BAR) will be measured to assess
vascular function. A 12 MHz linear array transducer and
ultrasound scanner (Vivid i, GE Healthcare, USA) will be
used to record the dilator response of the brachial artery
to increased blood flow generated during reactive hyper-
aemia of the downstream forearm. The measures will be
performed on the non-fistula arm (if a fistula is present).
A blood pressure cuff is placed on the upper aspect for the
lower forearm. The brachial artery will be scanned in the
longitudinal plane, acquiring a baseline image about five
cm above the antecubital fossa. The transducer is left in
this scanning position. The cuff is then inflated to 220
mmHg for four minutes. Following cuff deflation, images
will be acquired at five and 10 seconds then at 10-second
intervals up to 120 seconds. Following a 15-minute rest,
this process is then repeated. The 15-minute interval
allows the artery to return to its baseline state. The last
phase of the BAR test involves the administration of sub-
lingual GTN. Following a final 15-minute interval, a base-
line image is acquired and then 300 μg of sublingual GTN
will be administered. After three minutes, images of the
brachial artery will be obtained as described above. All
images will be stored for later offline analysis and archiv-
ing. The truest diameter of the brachial artery is indicated
by the "double line sign", which is the crisp intima-media
and media-adventitia boundaries on the near and far
walls [22]. For all measures, the average of three diameter
measurements made along the artery, from the trailing
edge of intima-media to the leading edge of the media-
adventitia, as described by Aeschlimann et al [22], will be
used. BAR will be expressed as maximal dilatation (mm),
and expressed as a percentage change from baseline. The
area under the diameter/time curve (AUC) will also be
used to determine temporal changes using analytical
imaging software (Imaging Research, St. Catherine's, Can-
ada) and confirming with trapezoidal integration in
Microsoft Excel (Seattle, WA, USA) as we have done previ-
ously [23]. These will then be compared with the dilata-
tion in response to the administration of GTN. This
provides a ratio of endothelial dependant and independ-
ent vascular function.
Myocardial Structure and Function
Transthoracic echocardiography (TTE) will be performed
to assess left atrial and left ventricular (LV) geometry and
myocardial systolic and diastolic function. The Vivid i (GE
healthcare, USA) with a phased-array ultrasound probe
(S3) will be used for these measures. Patients will be posi-
tioned in the left lateral recumbent position.Page 3 of 7
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(2D) and M-Mode measurements from the parasternal
long axis window. Measurements of the interventricular
septal wall thickness during diastole (IVSTd), posterior
wall thickness (PWT), LV internal dimension during dias-
tole (LVIDd) and LV internal dimension during systole
(LVIDs) will be measured to derive the Left Ventricular
Mass (LVmass).
LV mass will be calculated from LV linear dimensions
using the ASE recommended formula:
LVmass = 1.04 ((LVIDd + PWT + IVSTd (3 - LVIDd)3 × 0.8 
+ 0.6 g
These measures will then be divided by body surface area
to obtain Left Ventricular Mass Index (LVMI).
Relative wall thickness (RWT) will be calculated using the
American Society of Echocardiography (ASE) recom-
mended formula [24]:
(2× PWTd)/LVIDd
Patients will have concentric hypertrophy if RWT > 0.42
with increased LV mass; eccentric hypertrophy if RWT <
0.42 with increased LV mass and concentric remodelling
if the LV mass normal and RWT was increased[24]. Left
atrial (LA) volume will be measured then indexed to BSA,
using the area-length (L) method from the apical 4 (A4C)
and apical 2 (A2C) chamber views in accordance with ASE
guidelines [25]. L will be measured from the mid mitral
annular plane and mid posterior LA wall, along its true
long axis at end systole. During planimetry, the conflu-
ences of pulmonary veins and LA appendage are excluded.
LA Volume = (A1)(A2)/L × 0.85/BSA[26]
Where L = shorter length from either A4C or A2C. A1 = Max-
imal LA area from A4C. A2 = Maximal LA area from A2C.
LV systolic function will be assessed by calculating the
ejection fraction (EF) using the disc summation method
(Modified biplane Simpson's rule) [25]. Applying the fol-
lowing formula derives EF%:
Where LVEDV = left ventricular end diastolic volume,
LVESV = left ventricular end systolic volume. For the pur-
pose of this study, a normal EF will be ≥ 55% [25].
LV Diastolic Function will be performed using pulsed Dop-
pler interrogations of the LV inflow tract from the A4C view.
This will allow for the measurement of peak flow velocity of
early (E) and late (A) LV filling. Early diastolic flow (deceler-
ation time DT) and mitral A wave duration. The isovolumic
relaxation time (IVRT) will be recorded from the A5C view
using continuous wave Doppler interrogation.
Tissue Doppler Imaging (TDI) will measure the longitudi-
nal velocities within the myocardium from the apical 4-
chamber view, in pulse wave (PW) mode. This normally
consists of a positive systolic wave (S') and 2 diastolic
peaks, one during early diastole (E') and the second dur-
ing atrial contraction (A'). The mitral E velocity and annu-
lar E' will be compared as a ratio (E/E'). An E/E' > 10 from
the lateral wall is will be indicative of elevated LV filling
pressures [26]. Recordings will be made from the lateral
mitral annulus.
Pulse wave analysis (PWA) will be used to derive a central
(ascending aortic) pressure waveform via applanation
tonometry. This method involves using a generalised
transfer function to generate a central pressure waveform,
which we have shown to be valid [27]. Is a reproducible
technique for measuring central blood pressure during
hemodynamic perturbations induced by exercise [28].
The central waveform will be calibrated by the average of
two measures of brachial blood pressure using a semi-
automated device (UA-767, A&D). Central pulse pressure,
central systolic blood pressure and augmented pressure
will be recorded as markers of LV afterload.
Additional Measures of Arterial Stiffness
Augmentation index (AIx) is regarded as a measure of sys-
temic arterial stiffness that will be derived from the central
and radial pressure waveforms as previously described
[29]. The ratio of brachial to central pulse pressure (pulse
pressure amplification) will also be measured as a surro-
gate of large artery stiffness [30].
Oxidative Stress and Inflammation
Additional secondary outcome measures for oxidative
stress and antioxidant status will include plasma protein
carbonyls, total antioxidant capacity, plasma antioxidant
enzyme activities, and for inflammation, C reactive pro-
tein and a cytokine panel consisting of IL-6, IL-8, IL-10
and TNF-alpha.
Additional data to be collected will include self-reported
health (SF-36 questionnaire), physical activity levels
(items from the Active Australia questionnaire) nutri-
tional status (four-day diet diary), adverse events includ-
ing mortality, morbidity, hospitalizations and procedures
performed within the day procedure unit (e.g. iron infu-
sions and arterio-venous fistula formation).
Visit One (baseline data)
The study flow is summarized in Figure 1 and the study
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by the trial coordinator at which a date and time is agreed
for the subject to attend an appointment for baseline trial
measures. A letter of confirmation of this appointment
and a pathology request form will be posted (if consent
formed is signed). Patients will be asked to attend the
pathology laboratory at least seven days before their first
trial visit to have a fasting blood sample collected. At the
first trial visit, if not already done so, the consent form will
be signed and additional data will be obtained from the
medical records (medical history, medications) and meas-
ures of height, weight and blood pressure will be
recorded. PWV, PWA, CIMT, TTE and BAR measures will
then be made. At the completion of baseline data acquisi-
tion, the trial coordinator provides the subject with a
pathology request form, for which blood samples are
taken within the first week of visit one. The subject will be
provided with two questionnaires (SF 36 and items from
Active Australia) and a four-day diet diary for completion
to take home. The subject is supplied with a self-addressed
express post envelope. Subjects are asked to complete and
post these within the following two weeks. Data obtained
are transcribed onto case record forms for entry into a spe-
cifically designed trial database. Subjects are then
reminded that they will be contacted by telephone in
approximately five months to confirm an appointment
date and time for visit two.
Visits Two and Three
These visits occur at six months and one year after com-
mencement of dialysis. An envelope containing a letter
confirming appointment, pathology request forms, four-
day diet diary, SF 36 and physical activity surveys will be
mailed to patients. They will be asked to complete surveys
and the diet diary and to attend the pathology laboratory
seven days prior to visits. At these visits, data acquisition
from measures and tests described above will be per-
formed again. Patients will be examined on a non-haemo-
dialysis day for hemodialysis patients and during the non-
dwell phase period for peritoneal dialysis patients.
Withdrawal from Study
Subjects will be withdrawn from the study at their request,
without prejudice, as documented and explained at the
time of consenting.
Sample Size Estimates
Data from other studies indicates that pentraxin-3 has the
highest variability of the three primary outcome measures
(mean ± SD; isoprostanes = 54.1 ± 7.0 [46], PWV = 11.4 ±
2.4 [47], pentraxin 3 = 0.75 ± 0.3 [48]) and therefore will
be used to estimate the sample size required. We assume
that a decrease of 10% in pentraxin-3 would be clinically
significant. Therefore, with alpha = 0.05 and beta = (1–
0.8), we would need 23 patients in one of the groups. It is
expected with an initial enrolment of 80 patients, 60 will
complete the one-year measures. Based on the current dis-
tribution patterns within the renal services we estimate
that 37 of these patients will be receiving haemodialysis
and 23 receiving peritoneal dialysis.
Statistical analysis
All baseline continuous variables between groups will be
compared using general linear modelling, whilst categori-
cal variables will be compared using exact logistic regres-
sion. The rates of change will be estimated for each patient
separately by linear regression. general linear modeling,
will be used to compare the mean rate of change in pri-
mary outcome measures between groups, unadjusted and
adjusted for actual and potential confounding variables.
Mean differences, 95% confidence intervals and P-values
will be corrected for repeated measures, and P-values cor-
rected for multiple comparisons by the Holm method. All
Flow chart of the studyigure 1
Flow chart of the study.Page 5 of 7
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dows (StataCorp LP, College Station, Tx).
Discussion
The objective of this study is to assess whether peritoneal
dialysis will have less effect on arterial stiffness, vascular
function, myocardial structure and function, oxidative
stress and inflammation than hemodialysis. Comparing
the effects of renal replacement therapy modalities on sur-
rogate cardiovascular markers over time will provide
unique important information to assist in the treatment
of patients with ESKD. Data from this trial may also lead
to a larger scale study assessing the effect of dialysis
modality on major cardiovascular endpoints.
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